$CBAY..$1.24..Q1 catalyst in 2016 has hurt share price at it was suppose to be Q4 2015. Trading well below cash here. We could see tax loss selling in December but if so creates opportunity. People will be buying back into 2016. Just the way it goes on these biotechs sometimes. Missing their Q4 catalyst hurt them for year end run. Concerned it has not been moving higher on positive market days like today.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.